Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med.1999;340:115-126.
Williams JK, Sukhova GK, Herrington DM, Libby P. Pravastatin has cholesterol-lowering independent effects on the artery
wall of atherosclerotic monkeys. J Am Coll Cardiol.1998;31:684-691.
Shiomi M, Ito C. Effect of cerivastatin sodium, a new inhibitor of HMG-CoA reductase,
on plasma lipid levels, progression of atherosclerosis, and lesional composition
in the plaques of WHHL rabbits. Br J Pharmacol.1999;126:961-968.
Bustos C, Hernandez-Presa MA, Ortego M.
et al. HMG-CoA reductase inhibition with atorvastatin reduces neointimal inflammation
in a rabbit model of atherosclerosis. J Am Coll Cardiol.1998;32:2057-2064.
Ferro D, Parrotto S, Basili S.
et al. Simvastatin inhibits the monocyte expression of proinflammatory cytokines
in patients with hypercholesterolemia. J Am Coll Cardiol.2000;36:427-431.
Fukumoto Y, Libby P, Rabkin E.
et al. Statins alter smooth muscle cell accumulation and collagen content
in established atheroma of Wantanabe heritable hyperlipidemic rabbits. Circulation.2001;103:993-999.
Aikawa M, Rabkin E, Sugiyama S.
et al. Cerivastatin, an HMG-CoA reductase inhibitor, suppresses growth of
macrophages expressing matrix metalloproteinases and tissue factor in vivo
and in vitro. Circulation.2001;103:276-283.
Bellosta S, Via D, Canavesi M.
et al. HMG-CoA reductase inhibitors reduce MMP-9 secretion by macrophages. Arterioscler Thromb Vasc Biol.1998;18:1671-1678.
Crisby M, Fredriksson GN, Shah PK.
et al. Pravastatin treatment increases collagen content and decreases lipid
content, inflammation, metalloproteinases, and cell death in human carotid
plaques: implications for plaque stabilization. Circulation.2001;103:926-933.
Niwa S, Totsuka T, Hayashi S. Inhibitory effect of fluvastatin, an HMG-CoA reductase inhibitor, on
the expression of adhesion molecules on human monocyte cell line. Int J Immunopharmacol.1996;18:669-675.
Byington RP, Davis BR, Plehn JF.
et al. Reduction of stroke events with pravastatin: the Prospective Pravastatin
Pooling (PPP) Project. Circulation.2001;103:387-392.
Freeman DJ, Norrie J, Sattar N.
et al. Pravastatin and the development of diabetes mellitus: evidence for
a protective treatment effect in the West of Scotland Coronary Prevention
Ridker PM. High-sensitivity C-reactive protein: potential adjunct for global risk
assessment in the primary prevention of cardiovascular disease. Circulation.2001;103:1813-1818.
Ridker PM, Cushman M, Stampfer MJ.
et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently
healthy men. N Engl J Med.1997;336:973-979.
Ridker PM, Hennekens CH, Buring JE.
et al. C-reactive protein and other markers of inflammation in the prediction
of cardiovascular disease in women. N Engl J Med.2000;342:836-843.
Danesh J, Whincup P, Walker M.
et al. Low-grade inflammation and coronary heart disease: prospective study
and updated meta-analyses. BMJ.2000;321:199-204.
Ridker PM, Rifai N, Clearfield M.
et al. Measurement of C-reactive protein for the targeting of statin therapy
in the primary prevention of acute coronary events. N Engl J Med.In press.
Sacks FM, Pfeffer MA, Moye LA.
et al. for the Cholesterol and Recurrent Events Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction
in patients with average cholesterol levels. N Engl J Med.1996;335:1001-1009.
Ridker PM, Rifai N, Pfeffer MA.
et al. for the Cholesterol and Recurrent Events Trial Investigators. Inflammation, pravastatin, and the risk of coronary events after myocardial
infarction in patients with average cholesterol levels. Circulation.1998;98:839-844.
Ridker PM, Rifai N, Pfeffer MA.
et al. Long-term effects of pravastatin on plasma concentration of C-reactive
Ridker PM, Rifai N, Lowenthal SP. Rapid reduction in C-reactive protein with cerivastatin among 785 patients
with primary hypercholesterolemia. Circulation.2001;103:1191-1193.
Albert MA, Staggers J, Chew P, Ridker PM. The Pravastatin Inflammation/CRP Evaluation (PRINCE): rationale and
design. Am Heart J.2001;141:893-898.
Roberts WL, Molton L, Law TC.
et al. Evaluation of nine automated high sensitivity C-reactive protein methods:
implications for clinical and epidemiological application, II. Clin Chem.2001;47:418-425.
Kennon S, Price CP, Mills PG.
et al. The effect of aspirin on C-reactive protein as a marker of risk in
unstable angina. J Am Coll Cardiol.2001;37:1266-1270.
Ridker PM, Hennekens CH, Rifai N, Buring JE, Manson JE. Hormone replacement therapy and increased plasma concentration of C-reactive
Cushman M, Legault C, Barrett-Connor E.
et al. Effects of postmenopausal hormones on inflammation sensitive proteins:
the Postmenopausal Estrogen/Progestin Interventions (PEPI) Study. Circulation.1999;100:717-722.
Hulley S, Grady D, Bush T.
et al. for the Heart and Estrogen/Progestin Replacement Study (HERS) Research
Group. Randomized trial of estrogen plus progestin for secondary prevention
of coronary heart disease in postmenopausal women. JAMA.1998;280:605-613.
Ridker PM, Stampfer MJ, Rifai N. Novel risk factors for systemic atherosclerosis: a comparison of C-reactive
protein, fibrinogen, homocysteine, lipoprotein-a, and standard cholesterol
screening as predictors of peripheral arterial disease. JAMA.2001;285:2481-2485.
Shepard J, Cobb SM, Ford I.
et al. for the West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med.1995;333:1301-1307.
Long-term Intervention With Pravastatin in Ischaemic Disease (LIPID)
Study Group. Prevention of cardiovascular events and death with pravastatin in patients
with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med.1998;339:1349-1357.